|
NIAID describes research priorities to fight drug-resistant tuberculosis
April 23, 2008Tuberculosis (TB) has long been one of the world's great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.
A summary of the agenda, authored by NIAID Director Anthony S. Fauci, M.D., and members of the NIAID Tuberculosis Working Group, is now available online in The Journal of Infectious Diseases.
"The TB diagnostic tools in use today are antiquated, slow and insensitive; TB drug regimens are complex and lengthy; and the only vaccine available does not provide effective protection against adult pulmonary TB," says Dr. Fauci. "The challenge of TB control is further compounded by the rise of drug-resistant TB, and we anticipate that the NIAID Research Agenda for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis will contribute substantively to the fight against this emerging threat."
The World Health Organization (WHO) estimates that 500,000 people worldwide have MDR TB, while the frequently fatal XDR TB has been detected in 46 countries. Factors contributing to the rising tide of drug-resistant TB include
* Lack of routine testing to determine TB drug-sensitivity
* Incomplete treatment of people infected with TB-causing bacteria
* The epidemic of TB in HIV-infected people
* Limited TB research by pharmaceutical companies, resulting in few new anti-TB drugs or other interventions
The NIAID research agenda complements domestic and international efforts to prevent and control the spread of MDR and XDR TB. Whereas the WHO's STOP TB Partnership plan emphasizes increased surveillance and control and treatment efforts, the NIAID agenda focuses on biomedical research. The Institute also collaborates with the Centers for Disease Control and Prevention and other NIH Institutes and Centers on TB research efforts in the United States.
To prevent the further emergence and spread of MDR and XDR TB, the NIAID agenda identifies areas of biomedical research that are likely to contribute substantially to a global public health response. Building on existing efforts within the international network of TB research, NIAID's priorities include efforts to
* Develop and test reliable technologies to rapidly diagnose TB and to identify drug resistance
* Define the most effective use of existing TB therapies and other antibiotics available to treat drug-resistant TB and develop new drugs, particularly to treat MDR and XDR TB
* Better understand the basic biology of TB-causing bacteria and their interaction with the human host that underlie the development of drug-resistant TB
* Understand the epidemiology of drug-resistant TB
* Investigate the various manifestations of TB in adults, children and those with co-infections, including HIV/AIDS
* Conduct research to develop new vaccines and other preventive strategies
NIAID is leading and sponsoring research activities to create a foundation of knowledge for the discovery of new diagnostics, drugs and vaccines. The Institute also supports the efforts of organizations, such as drug companies and public-private partnerships, to further develop these products into tools and approaches that enhance the quality of care for people with TB.
"Only a concerted global effort can counteract the rise of drug-resistant TB," notes Dr. Fauci. "Development of improved diagnostics and better treatment and control strategies will depend on collaboration with our partners at every research step, from basic science to large clinical trials."
NIH/National Institute of Allergy and Infectious Diseases
The World Health Organization (WHO) estimates that 500,000 people worldwide have MDR TB, while the frequently fatal XDR TB has been detected in 46 countries. Factors contributing to the rising tide of drug-resistant TB include
* Lack of routine testing to determine TB drug-sensitivity
* Incomplete treatment of people infected with TB-causing bacteria
* The epidemic of TB in HIV-infected people
* Limited TB research by pharmaceutical companies, resulting in few new anti-TB drugs or other interventions
The NIAID research agenda complements domestic and international efforts to prevent and control the spread of MDR and XDR TB. Whereas the WHO's STOP TB Partnership plan emphasizes increased surveillance and control and treatment efforts, the NIAID agenda focuses on biomedical research. The Institute also collaborates with the Centers for Disease Control and Prevention and other NIH Institutes and Centers on TB research efforts in the United States.
To prevent the further emergence and spread of MDR and XDR TB, the NIAID agenda identifies areas of biomedical research that are likely to contribute substantially to a global public health response. Building on existing efforts within the international network of TB research, NIAID's priorities include efforts to
* Develop and test reliable technologies to rapidly diagnose TB and to identify drug resistance
* Define the most effective use of existing TB therapies and other antibiotics available to treat drug-resistant TB and develop new drugs, particularly to treat MDR and XDR TB
* Better understand the basic biology of TB-causing bacteria and their interaction with the human host that underlie the development of drug-resistant TB
* Understand the epidemiology of drug-resistant TB
* Investigate the various manifestations of TB in adults, children and those with co-infections, including HIV/AIDS
* Conduct research to develop new vaccines and other preventive strategies
NIAID is leading and sponsoring research activities to create a foundation of knowledge for the discovery of new diagnostics, drugs and vaccines. The Institute also supports the efforts of organizations, such as drug companies and public-private partnerships, to further develop these products into tools and approaches that enhance the quality of care for people with TB.
"Only a concerted global effort can counteract the rise of drug-resistant TB," notes Dr. Fauci. "Development of improved diagnostics and better treatment and control strategies will depend on collaboration with our partners at every research step, from basic science to large clinical trials."
NIH/National Institute of Allergy and Infectious Diseases
Tuberculosis News and Current Tuberculosis Events RSSPilot study reinforces use of portable anteroom HEPA filtration
Amidst an increase in new tuberculosis cases, researchers have begun investigating the effectiveness of new operating room filtration systems designed to protect staff and patients.
X-rays power discoveries at Chicago's Field Museum
Digital medical imaging and information technology from Carestream Health, Inc., is playing a key role in helping The Field Museum of Chicago discover and analyze secrets hidden within its world-class collections.
Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence
New findings show a link between micronutrient supplementation and reduced risk of recurrence during tuberculosis chemotherapy, according to a study published in the June 1 issue of The Journal of Infectious Diseases, now available online.
Scientists test device to track medication adherence in patients with HIV/AIDS
Most of us have missed a dose of antibiotic or forgotten to take a daily vitamin. But when the stakes are higher - as they are for people with HIV/AIDS - a skipped pill could mean the difference between health and hazard for the entire population.
University of Arizona scientist shares in discovery of microbe filaments' power
Researchers from The University of Arizona and Columbia University have discovered that tiny filaments on bacteria can bundle together and pull with forces far stronger than experts had previously thought possible.
Researchers pilot new electronic system for infectious illness
Researchers at Harvard Pilgrim Health Care, Harvard Medical School, Atrius Health, and the Massachusetts Department of Public Health have created and tested a set of computer programs that use electronic medical records to help clinicians detect contagious illness and automatically report them to public health departments.
'Healing clays' show promise for fighting deadly MRSA superbug infections, other diseases
Mud may be coming to a medicine cabinet or pharmacy near you. Scientists in Arizona report that minerals from clay could form the basis of a new generation of inexpensive, highly-effective antimicrobials for fighting MRSA infections that are moving out of health care settings and into the community.
Better and faster: Distinguishing non-TB pulmonary disease from TB
A diagnostic kit shows new promise for distinguishing between tuberculosis (TB) and its infections from disease caused by related mycobacteria family, which mimic TB and other lung disease in symptoms but require distinctly different clinical treatments.
Smear campaign: Faster detection of multidrug-resistant TB for public health
There is a new tool in the arsenal to fight multidrug-resistant tuberculosis (MDR-TB): a rapid diagnostic test that can function in high-burden settings such as public health clinics.
The complexities of genetic susceptibility to tuberculosis revealed
Researchers working in Vietnam have identified a genetic variant that predisposes people to developing a lethal form of tuberculosis (TB), tuberculous meningitis, if they are infected with a strain of TB known as the Beijing strain.
More Tuberculosis News Articles
 | The Air We Breathe: A Novel by Andrea Barrett |
 | Illness as Metaphor and AIDS and Its Metaphors by Susan Sontag |
 | Virgin River: A Barnaby Skye Novel (Skye's West) by Richard S. Wheeler |
 | Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman |
 | Identification Problems in the Social Sciences by Charles F. Manski |
 | Towns of the Sandia Mountains (NM) (Images of America) by Mike Smith |
 | The Night Journal by Elizabeth Crook |
 | The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan |
 | Behold the Many: A Novel by Lois-Ann Yamanaka |
 | The White Plague: Tuberculosis, Man, and Society by Rene J. Dubos |
| © 2008 BrightSurf.com |